Pegaptanib octasodium for the treatment of diabetic macular edema

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1317-1323

  Schartman, Jerome P ^a   Coney, Joseph M ^a   Hornik, Joan H ^a   Miller, David G ^a  

^a Retina Associates of Cleveland   (United States)

Author keywords

anti VEGF; antivascular endothelial growth factor; bevacizumab; clinical trials; diabetic macular edema; pegaptanib; photocoagulation; ranibizumab; visual acuity

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ARTICLE; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INJURY; GERIATRIC PATIENT; HUMAN; LASER COAGULATION; LENS INJURY; LOW LEVEL LASER THERAPY; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; OPTICAL COHERENCE TOMOGRAPHY; PHARMACODYNAMICS; RETINA DETACHMENT; RETINA MACULA HOLE; SUBCONJUNCTIVA HEMORRHAGE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

APTAMERS, NUCLEOTIDE; CLINICAL TRIALS, PHASE II AS TOPIC; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955852527     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.579902     Document Type: Article

References (51)

1. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema.Report number 1.Arch Ophthalmol 1985;103:1796-806
2. Diabetic Retinopathy Clinical Research Network.Randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.Ophthalmology 2008;115:1447-59
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al.VEGF inhibition study in ocular neovascularization clinical trial group.Pegaptanib for neovascular age-related macular degeneration.N Eng J Med 2004;351:2805-16
4. Ng EW, Adamis AP.Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.Ann NY Acad Sci 2006;1082:151-71 (Pubitemid 44955460)
5. Cunningham ET Jr, Adamis AP, Altaweel M, et al.A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.Ophthalmology 2005;112:1747-57
6. Holz FG.Pfizer A5751013 Trial, A phase 2/3 randomized, controlled, double-masked, multi-center, comparative trial, in parallel groups, compares the safety and efficacy of intravitreous injections of 0.3 mg pegaptanib sodium (Macugen-), given as often as every 6 weeks for 2 years, to sham injections, in subjects with diabetic macular edema (DME).Data presented at the World Ophthalmology Congress, 9 June 2010, Berlin, Germany
7. Ciulla TA, Amador AG.Zinman B.Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.Diabetes Care 2003;26:2653-64 (Pubitemid 37055447)
8. Antcliff RJ, Marshall J.The pathogenesis of edema in diabetic maculopathy.Semin Ophthalmol 1999;14:223-32 (Pubitemid 30061165)
9. Gardner TW, Antonetti DA, Barber AJ, et al.Diabetic retinopathy: more than meets the eye.Surv Ophthalmol 2002;47(Suppl 2):S253-62 (Pubitemid 36351245)
10. Lu M, Perez VL, Ma N, et al.VEGF increases retinal vascular ICAM-1 expression in vivo.Invest Ophthalmol Vis Sci 1999;40:1808-12 (Pubitemid 29297158)
11. Barleon B, Sozzani S, Zhou D, et al.Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.Blood 1996;87:3336-43 (Pubitemid 26115364)
12. Wang J, Xu X, Elliott MH, et al.Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage.Diabetes 2010;59:2297-305
13. Tolentino MJ, Miller JW, Gragoudas ES, et al.Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.Ophthalmology 1996;103:1820-8 (Pubitemid 26403735)
14. Cladwell RB, Bartoli M, Behzadian MA, et al.Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.Diabetes Metab Res Rev 2003;19:442-55 (Pubitemid 37536961)
15. Nashijima K, Ng Y-S, Zhong L, et al.VEGF-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.Am J Pathol 2007;171:53-67 (Pubitemid 47339226)
16. Kamba T, Tam BY, Hashizume H, et al.VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.Am J Physiol Heart Circ Physiol 2006;290:H560-76
17. Ishida S, Usui T, Yamashiro K, et al.VEGF-164 is proinflammatory in the diabetic retina.Invest Ophthalmol Vis Sci 2003;44:215562
18. Ishida S, Usui T, Yamashiro K, et al.VEGF-164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.J Exp Med 2003;198:483-9 (Pubitemid 36976059)
19. Adamis AP, Ataweel M, Bressler NM, et al.Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.Ophthalmology 2006;113:23-8 (Pubitemid 43021723)
20. Peters S, Heiduschka P, Julien S, et al.Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.Am J Ophthalmol 2007;143:995-1002
21. Chung EJ, Roh MI, Kwon OW, et al.Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.Retina 2008;28:957-63
22. Salam A, DaCosta J, Sivaprasad S.Anti-vascular endothelial growth factor agents for diabetic maculopathy.Br J Ophthalmol 2010;94:821-6
23. Querques G, Bux AV, Martinelli D, et al.Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema.Acta Ophthalmol 2009;87:623-30
24. Querques G, Bux AV, Fusco AR, et al.Pegaptanib sodium versus pegaptanib sodium combined with macular laser photocoagulation or laser alone for diabetic macular edema [article ID 672178].J Ophthalmol 2009: published online 9 March 2010, doi:10.1155/2009/672178
25. NeLM news service.Phase III study shows pegaptanib sodium improved vision over standard of care in patients with diabetic macular edema.24 June 2010.Available from: http://www.nelm.nhs.uk/en/NeLM-Area/News/2010-June/24/ Phase-III-study-shows-pegaptanibsodium- improved-vision-over-standard- of-care-in-patients-with-diabetic-macularoedema/? query=pegaptanib&rank=100 [Last accessed 1 December 2010]
26. DAmico DJ, Masonson HN, Patel M, et al.; VEGF inhibition study in ocular neovascularization (VISION) clinical trial group.Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.Ophthalmology 2006;113:992-1001
27. Singerman LJ, Masonson H, Patel M, et al.Pegaptanib sodium for neovascular age-related macular degeneration: third year safety results of the VEGF inhibition study in ocular neovascularization (VISION) trial.Br J Ophthalmol 2008;92:1606-11
28. Salz D, Prenner J, Cunningham ET Jr.Local complications of IV Anti-VEGF therapy.Rev Ophthalmol 2010;11:66-74
29. Ciulla TA, Starr MB, Masket S.Bacterial endophthalmitis prophylaxis for cataract surgery.An evidence-based update.Ophthalmology 2002;109:13-24 (Pubitemid 34027416)
30. Falkenstein IA, Chang L, Freeman WR.Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).Retina 2007;27:1044-7 (Pubitemid 350304005)
31. Good TJ, Kimura AE, Mandava N, Kahook MY.Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.Br J Ophthalmol 2010: published online 11 August 2010, doi:10.1136/bjo.2010.180729
32. Frenkel RE, Mani L, Toler AR, Frenkel MP.Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.Am J Ophthalmol 2007;143:1034-5 (Pubitemid 46764645)
33. Kim JE, Mantravadi AV, Hur EY, Covert DJ.Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.Am J Ophthalmol 2008;146:930-4
34. Sniegowski M, Mandava N, Kahook MY.Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis.Open Ophthalmol J 2010;4:28-9
35. Kahook MY, Liu L, Ruzycki P, et al.High-molecular-weight aggregates in repackaged bevacizumab.Retina 2010;30:887-92
36. De Franciscis V, Esposito CL, Catuogno S, et al.Aptamers as innovative diagnostic and therapeutic agents in the central nervous system.CNS Neurol Disord Drug Targets 2009;8:393-401
37. Ladas ID, Karagiannis DA, Rouvas AA, et al.Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2000 injections.Retina 2009;29:313-8
38. Wickremasinghe SS, Michalova K, Gilhotra J, et al.Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.Ophthalmology 2008;115:1911-5
39. Mason JO, Wigton EH, Emond TL.Prevention of recurrent bevacizumab-induced intraocular inflammation [poster 408].American Academy of Ophthalmology Annual Meeting, 16 - 19 October 2010, Chicago IL, USA.
40. Agawa T, Usui Y, Wakabayashi Y, et al.Increased intraocular concentrations of various cytokines in AMD treated with intravitreal injection of bevacizumab [poster 219].American Academy of Ophthalmology Annual Meeting, 16 - 19 October 2010, Chicago IL, USA.
41. Mansour AM, Bynoe LA, Welch JC, et al.Retinal vascular events after intravitreal bevacizumab.Acta Ophthalmol 2010;88:730-5
42. Shima C, Sakaguchi H, Gomi F, et al.Complications in patients after intravitreal injection of bevacizumab.Acta Ophthalmol 2008;86:372-6
43. Papadopoulou DN, Mendrinos E, Mangioris G, et al.Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.Ophthalmology 2009;116:1755-61
44. Soliman W, Vinten M, Sander B, et al.Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.Acta Ophthalmol 2008;86:365-71
45. Bakri SJ, Snyder MR, Reid JM, et al.Pharmacokinetics of intravitreal bevacizumab (Avastin).Ophthalmology 2007;114:855-9 (Pubitemid 46635858)
46. Van Wijngaarden P, Coster DJ, Williams KA.Inhibitors of ocular neovascularization: promises and potential problems.JAMA 2005;293:1509-13 (Pubitemid 40393297)
47. Yang JC, Haworth L, Sherry RM, et al.A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.N Eng J Med 2003;349:427-34 (Pubitemid 36910021)
48. Hurwitz H, Fehrenbacher L, Novotny W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Eng J Med 2004;350:2335-42 (Pubitemid 38702844)
49. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al.Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.Ophthalmology 2006;113:1-12
50. Curtis LH, Hammill BG, Schulman KA, Cousins SW.Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for macular degeneration.Arch Ophthalmol 2010;128:1273-9
51. Eyetech Announces Program to Develop Extended-Release Formulation of Macugen.Available from: http://www.bioportfolio.com/news/article/196415/Eyetech- Announces-Program-To- Develop-Extended-release-Formulation- Of-Macugen-r.html [Last accessed 30 November 2010].